2019 Medicines For Europe Legal Affairs Conference 07/03/2019 by Intellectual Property Watch, Intellectual Property Watch 1 Comment Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)Advertisement: The 2019 Medicines for Europe Legal Affairs Conference will take place, for the first time, in Amsterdam. In its 15th edition, this conference will provide participants with the opportunity to exchange views and share ideas with leading industry executives and experts, counsel and European institution officials around the latest developments in intellectual property and legal affairs concerning generic, biosimilar and value added medicines within Europe and worldwide. The conference will address: – A General Counsel discussion on international developments around IP and competition – What to expect from the pharma incentives review and from the Supplementary Protection Certificate (SPC) Regulation – The SPC Manufacturing Waiver: what conclusions can be drawn? – Brexit: the IP landscape and business strategies for the sector – What Image Credits: Medicines for Europe Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Related Intellectual Property Watch may be reached at info@ip-watch.org."2019 Medicines For Europe Legal Affairs Conference" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
[…] Based on who's attending and participating, #MedicinesForEurope has nothing to do with Europe (or medicines for it). It's the bloody cartel that is killing poor Europeans to jack up their prices. http://www.ip-watch.org/2019/03/07/2019-medicines-europe-legal-affairs-conference/ […] Reply
